keyword
MENU ▼
Read by QxMD icon Read
search

methylphenidate adhd

keyword
https://www.readbyqxmd.com/read/28651152/methylphenidate-disintegration-from-oral-formulations-for-intravenous-use-by-experienced-substance-users
#1
G D Bjarnadottir, M Johannsson, A Magnusson, B O Rafnar, E Sigurdsson, S Steingrimsson, V Asgrimsson, I Snorradottir, H Bragadottir, H M Haraldsson
BACKGROUND AND AIMS: Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. MPH is currently the preferred substance among most intravenous (i.v.) substance users in Iceland. Four types of MPH preparations were available in Iceland at the time of study: Immediate-release (IR), sustained-release (SR), osmotic controlled-release oral delivery (OROS) tablet and osmotic-controlled release (OCR). MPH OROS has previously been rated the least desirable by i...
June 13, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28649058/buspirone-attenuates-methylphenidate-induced-growth-inhibition
#2
Nausheen Alam, Rahila Najam
Methylphenidate is effective in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults, but its long term use can cause potential adverse effect on growth rate and variable effects on appetite. Previous studies have shown that long term administration of psychostimulant drugs increases the effectiveness of somatodendritic 5-hydroxytryptamine (5-HT)-1A receptors. Repeated administration of buspirone attenuates the effectiveness of somatodendritic 5-HT1A receptors. The present study was designed to test the hypothesis that co-administration of buspirone may attenuate methylphenidate-induced effects on growth rate and food intake...
March 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28647012/striatal-activation-predicts-differential-therapeutic-responses-to-methylphenidate-and-atomoxetine
#3
Kurt P Schulz, Anne-Claude V Bédard, Jin Fan, Thomas B Hildebrandt, Mark A Stein, Iliyan Ivanov, Jeffrey M Halperin, Jeffrey H Newcorn
OBJECTIVE: Methylphenidate has prominent effects in the dopamine-rich striatum that are absent for the selective norepinephrine transporter inhibitor atomoxetine. This study tested whether baseline striatal activation would predict differential response to the two medications in youth with attention-deficit/hyperactivity disorder (ADHD). METHOD: A total of 36 youth with ADHD performed a Go/No-Go test during functional magnetic resonance imaging at baseline and were treated with methylphenidate and atomoxetine using a randomized cross-over design...
July 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28640990/opiate-antagonists-do-not-interfere-with-the-clinical-benefits-of-stimulants-in-adhd-a-double-blind-placebo-controlled-trial-of-the-mixed-opioid-receptor-antagonist-naltrexone
#4
Thomas J Spencer, Pradeep Bhide, Jinmin Zhu, Stephen V Faraone, Maura Fitzgerald, Amy M Yule, Mai Uchida, Andrea E Spencer, Anna M Hall, Ariana J Koster, Joseph Biederman
OBJECTIVE: Methylphenidate activates μ-opioid receptors, which are linked to euphoria. μ-Opioid antagonists, such as naltrexone, may attenuate the euphoric effects of stimulants, thereby minimizing their abuse potential. This study assessed whether the combination of naltrexone with methylphenidate is well-tolerated while preserving the clinical benefits of stimulants in subjects with attention-deficit/hyperactivity disorder (ADHD). METHODS: We conducted a 6-week, double-blind, placebo-controlled, randomized clinical trial of naltrexone in adults with DSM-IV ADHD receiving open treatment with a long-acting formulation of methylphenidate from January 2013 to July 2015...
June 20, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28633952/chronic-methylphenidate-regulates-genes-and-proteins-mediating-neuroplasticity-in-the-juvenile-rat-brain
#5
Emmanuel Quansah, Tiziana Sgamma, Estabraq Jaddoa, Tyra S C Zetterström
Methylphenidate (MPH) is the front-line psychostimulant medication prescribed for alleviating the symptoms associated with attention deficit hyperactivity disorder (ADHD) in children. Here, we investigated the effects of chronic MPH (2.0mg/kg, twice daily for 15 days) exposure to young rats (20-25days old at start of treatment) on the expression of genes and proteins associated with neuroplasticity, such as activity regulated cytoskeleton-associated protein (Arc), insulin receptor substrate protein 53 (IRSp53), cell division control protein 42 (Cdc42), and actin-related protein 2 (Arp2)...
June 17, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28631099/discontinuation-of-pharmacological-treatment-of-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-meta-analysis-of-63-studies-enrolling-11-788-patients
#6
M Riera, X Castells, A Tobias, R Cunill, L Blanco, D Capellà
BACKGROUND: The risk-benefit balance of pharmacological treatment for children and adolescents with ADHD and the factors that moderate this relationship are unclear. METHODS: A systematic review and meta-analysis of randomised, placebo-controlled clinical trials (RPCCTs) investigating the efficacy of pharmacological treatment in children or adolescents with ADHD was carried out. Meta-analysis of treatment discontinuation, clinician-, parent- and teacher-rated efficacy and adverse events was performed...
June 19, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28628269/effect-of-food-intake-on-the-pharmacokinetics-of-a-novel-methylphenidate-extended-release-oral-suspension-for-attention-deficit-hyperactivity-disorder
#7
Floyd R Sallee, Donna R Palumbo, Richat Abbas, Sally A Berry, Shivanand P Puthli, Kalyan K Kathala
We conducted an open-label, single-dose, randomized, crossover study in healthy adults to assess the impact of food on the bioavailability of 60 mg methylphenidate extended-release oral suspension (MEROS; Quillivant XR™)-a long-acting stimulant for the treatment of attention deficit hyperactivity disorder-by comparing the pharmacokinetic parameters under fed and fasting conditions. When MEROS 60 mg was administered under fed conditions compared with fasting conditions, the exposure of methylphenidate (d enantiomer) was higher, with a mean area under the plasma concentration-vs-time curve (AUC)0-t of 160...
June 19, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28617801/gastrointestinal-adverse-events-during-methylphenidate-treatment-of-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-a-systematic-review-with-meta-analysis-and-trial-sequential-analysis-of-randomised-clinical-trials
#8
Mathilde Holmskov, Ole Jakob Storebø, Carlos R Moreira-Maia, Erica Ramstad, Frederik Løgstrup Magnusson, Helle B Krogh, Camilla Groth, Donna Gillies, Morris Zwi, Maria Skoog, Christian Gluud, Erik Simonsen
OBJECTIVES: To study in more depth the relationship between type, dose, or duration of methylphenidate offered to children and adolescents with attention deficit hyperactivity disorder and their risks of gastrointestinal adverse events based on our Cochrane systematic review. METHODS AND FINDINGS: We use data from our review including 185 randomised clinical trials. Randomised parallel-group trials and cross-over trials reporting gastrointestinal adverse events associated with methylphenidate were included...
2017: PloS One
https://www.readbyqxmd.com/read/28616427/specific-genes-associated-with-adverse-events-of-methylphenidate-use-in-the-pediatric-population-a-systematic-literature-review
#9
REVIEW
Beinta Joensen, Morten Meyer, Lise Aagaard
The aim of this study was to review empirical studies examining associations between candidate genes and adverse events (AEs) from methylphenidate (MPH) use in children and adolescents. The PubMed, EMBASE, CINAHL, and Web of Science databases were searched from their inception until March 2017. We included empirically based articles on pharmacogenetic studies in 0-17-year-old patients that investigated associations between specific candidate genes, their polymorphisms, and reported AEs. We extracted information about study design, setting, type of AE reporter, studied genes and their polymorphisms, age and gender, administered doses, method of genotyping, outcome measures, and main findings...
April 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/28608744/methylphenidate-related-improvements-in-math-performance-cannot-be-explained-by-better-cognitive-functioning-or-higher-academic-motivation-evidence-from-a-randomized-controlled-trial
#10
Anne Fleur Kortekaas-Rijlaarsdam, Marjolein Luman, Edmund Sonuga-Barke, Pierre Bet, Jaap Oosterlaan
OBJECTIVE: This study investigated whether improvements in working memory, reaction time, lapses of attention, interference control, academic motivation, and perceived competence mediated effects of methylphenidate on math performance. METHOD: Sixty-three children (ADHD diagnosis; methylphenidate treatment; age 8-13; IQ > 70) were randomly allocated to a 7-day methylphenidate or placebo treatment in this double-blind placebo-controlled crossover study and compared with 67 controls...
June 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28590363/ethanol-interactions-with-dexmethylphenidate-and-dl-methylphenidate-spheroidal-oral-drug-absorption-systems-in-healthy-volunteers
#11
Hao-Jie Zhu, Kennerly S Patrick, Arthur B Straughn, Owen T Reeves, Hilary Bernstein, Jian Shi, Heather J Johnson, Joshua M Knight, Aaron T Smith, Robert J Malcolm, John S Markowitz
BACKGROUND/PURPOSE: Ethanol coadministered with immediate-release dl-methylphenidate (dl-MPH) or dexmethylphenidate (d-MPH) significantly increases the geomean maximum plasma concentration (Cmax) of d-MPH 22% and 15%, respectively, and elevates overall drug exposure and psychostimulant effects. We asked the question: Are these ethanol-MPH interactions based more fundamentally on (1) inhibition of postabsorption d-MPH metabolism or (2) acceleration of MPH formulation gastric dissolution by ethanol in the stomach? This was investigated using the pulsatile, distinctly biphasic, spheroidal oral drug absorption systems of dl-MPH and d-MPH...
August 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28558473/theory-of-mind-and-empathy-in-children-with-adhd
#12
Hagai Maoz, Hila Z Gvirts, Maya Sheffer, Yuval Bloch
OBJECTIVE: The current study compared empathy and theory of mind (ToM) between children with ADHD and healthy controls, and assessed changes in ToM among children with ADHD following administration of methylphenidate (MPH). METHOD: Twenty-four children with ADHD (mean age = 10.3 years) were compared with 36 healthy controls. All children completed the interpersonal reactivity index (IRI), a self-reported empathy questionnaire, and performed the "faux-pas" recognition task (FPR)...
May 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28557548/efficacy-and-safety-of-a-chewable-methylphenidate-extended-release-tablet-in-children-with-attention-deficit-hyperactivity-disorder
#13
Sharon B Wigal, Ann Childress, Sally A Berry, Heidi Belden, Faith Walters, Phillip Chappell, Nancy Sherman, John Orazem, Donna Palumbo
OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with placebo in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Following a 6-week, open-label, dose-optimization period, children 6-12 years of age (n = 90) with ADHD were randomly assigned to double-blind MPH ERCT at the final optimized dose (20-60 mg/day) or placebo...
May 30, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28551715/direct-comparison-of-the-acute-subjective-emotional-autonomic-and-endocrine-effects-of-mdma-methylphenidate-and-modafinil-in-healthy-subjects
#14
Patrick C Dolder, Felix Müller, Yasmin Schmid, Stefan J Borgwardt, Matthias E Liechti
RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. Little is known about differences in the acute effects of equally cardiostimulant doses of these stimulant-type substances compared directly within the same subjects. METHODS: We investigated the acute autonomic, subjective, endocrine, and emotional effects of single doses of MDMA (125 mg), methylphenidate (60 mg), modafinil (600 mg), and placebo in a double-blind, cross-over study in 24 healthy participants...
May 27, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28544581/a-comparison-of-the-pharmacokinetics-of-methylphenidate-extended-release-orally-disintegrating-tablets-with-a-reference-extended-release-formulation-of-methylphenidate-in-healthy-adults
#15
Ann Childress, Jeffrey G Stark, Russ McMahen, Dorothy Engelking, Carolyn Sikes
Extended-release (ER) methylphenidate (MPH) is a first-line treatment for attention-deficit/hyperactivity disorder. A methylphenidate extended-release orally disintegrating tablet (MPH XR-ODT) has recently been developed. This was a randomized, open-label, 3-period, 3-treatment study comparing the bioavailability and absorption of 2 MPH XR-ODT formulations with an MPH ER reference medication. Here we report the 2 treatments comparing the commercial MPH XR-ODT formulation and reference medication. Following a ≥10-hour fast, 42 healthy adults received 60 mg of reference medication or MPH XR-ODT (2 × 30 mg)...
May 25, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28544344/fed-and-fasted-administration-of-a-novel-extended-release-methylphenidate-orally-disintegrating-tablet-formulation-for-the-treatment-of-adhd
#16
Richard H Weisler, Jeffrey G Stark, Carolyn Sikes
Extended-release methylphenidate is a first-line treatment for attention-deficit/hyperactivity disorder. A methylphenidate extended-release orally disintegrating tablet (MPH XR-ODT) has recently been developed. Here we report an open-label, randomized, 2-period, 2-treatment crossover study to determine the effect of food on the bioavailability of a single 60-mg dose of MPH XR-ODT in healthy adults. Blood samples were collected predose through 36 hours postdose. Maximum plasma concentration (Cmax ), time to maximum plasma concentration (Tmax ), terminal elimination half-life (T1/2 ), overall systemic exposure (AUClast and AUCinf ), and partial areas under the concentration curve (AUC0-3 , AUC3-7 , and AUC7-12 ) were calculated...
May 25, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28534274/exploring-the-validity-of-proposed-transgenic-animal-models-of-attention-deficit-hyperactivity-disorder-adhd
#17
REVIEW
June Bryan de la Peña, Irene Joy Dela Peña, Raly James Custodio, Chrislean Jun Botanas, Hee Jin Kim, Jae Hoon Cheong
Attention-deficit/hyperactivity disorder (ADHD) is a common, behavioral, and heterogeneous neurodevelopmental condition characterized by hyperactivity, impulsivity, and inattention. Symptoms of this disorder are managed by treatment with methylphenidate, amphetamine, and/or atomoxetine. The cause of ADHD is unknown, but substantial evidence indicates that this disorder has a significant genetic component. Transgenic animals have become an essential tool in uncovering the genetic factors underlying ADHD. Although they cannot accurately reflect the human condition, they can provide insights into the disorder that cannot be obtained from human studies due to various limitations...
May 22, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28527021/comorbidity-prevalence-and-treatment-outcome-in-children-and-adolescents-with-adhd
#18
Laura Reale, Beatrice Bartoli, Massimo Cartabia, Michele Zanetti, Maria Antonella Costantino, Maria Paola Canevini, Cristiano Termine, Maurizio Bonati
Although ADHD comorbidity has been widely studied, some issues remain unsolved. This multicenter observational study aims to examine comorbid psychiatric disorders in a clinical sample of newly diagnosed, treatment naïve children and adolescents with and without ADHD and, to compare treatment efficacy based on the type of comorbidity. We performed an analysis of the medical records of patients identified from the Regional ADHD Registry database, enrolled in 18 ADHD centers in the 2011-2016 period. 1919 of 2861 subjects evaluated (67%) met the diagnostic criteria for ADHD: 650 (34%) had only ADHD, while 1269 (66%) had at least one comorbid psychiatric disorder (learning disorders, 56%; sleep disorders, 23%; oppositional defiant disorder, 20%; anxiety disorders, 12%)...
May 19, 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/28507595/differential-therapeutic-effects-of-atomoxetine-and-methylphenidate-in-childhood-attention-deficit-hyperactivity-disorder-as-measured-by-near-infrared-spectroscopy
#19
Yoko Nakanishi, Toyosaku Ota, Junzo Iida, Kazuhiko Yamamuro, Naoko Kishimoto, Kosuke Okazaki, Toshifumi Kishimoto
BACKGROUND: The stimulant methylphenidate (MPH) and the nonstimulant atomoxetine (ATX) are the most commonly-prescribed pharmacological treatments for attention deficit/hyperactivity disorder (ADHD). However, the drug-specific mechanism of action on brain function in ADHD patients is not well known. This study examined differences in prefrontal hemodynamic activity between MPH and ATX in children with ADHD as measured by near-infrared spectroscopy (NIRS) using the Stroop color-word task...
2017: Child and Adolescent Psychiatry and Mental Health
https://www.readbyqxmd.com/read/28506353/-effect-of-baicalin-on-atpase-and-ldh-and-its-regulatory-effect-on-the-ac-camp-pka-signaling-pathway-in-rats-with-attention-deficit-hyperactivity-disorder
#20
Rong-Yi Zhou, Jiao-Jiao Wang, Yue You, Ji-Chao Sun, Yu-Chen Song, Hai-Xia Yuan, Xin-Min Han
OBJECTIVE: To study the effect of baicalin on synaptosomal adenosine triphosphatase (ATPase) and lactate dehydrogenase (LDH) and its regulatory effect on the adenylate cyclase (AC)/cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway in rats with attention deficit hyperactivity disorder (ADHD). METHODS: A total of 40 SHR rats were randomly divided into five groups: ADHD model, methylphenidate hydrochloride treatment (0.07 mg/mL), and low-dose (3...
May 2017: Zhongguo Dang Dai Er Ke za Zhi, Chinese Journal of Contemporary Pediatrics
keyword
keyword
116871
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"